TranS1 is a medical device company focused on designing, developing and marketing products that implement its proprietary minimally invasive surgical approach to treat degenerative disc disease affecting the lower lumbar region of the spine. TranS1 currently markets two single-level fusion products, the AxiaLIF(r) and the AxiaLIF 360(tm), in the U.S. and Europe. In addition the company currently markets a two-level fusion product, the AxiaLIF 2L(tm), in Europe. TranS1 was founded in May 2000 and is headquartered in Wilmington, North Carolina. For more information, visit http://www.trans1.com.